Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$28.46+11.0%$22.56$13.74▼$70.43$6.44B2.4332.76 million shs25.37 million shsNVONovo Nordisk A/S$46.02+0.5%$38.71$35.12▼$81.44$205.70B0.7718.72 million shs11.99 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+10.85%+4.02%+44.23%+23.64%-45.34%NVONovo Nordisk A/S+0.53%+4.96%+22.99%-3.54%-31.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$28.46+11.0%$22.56$13.74▼$70.43$6.44B2.4332.76 million shs25.37 million shsNVONovo Nordisk A/S$46.02+0.5%$38.71$35.12▼$81.44$205.70B0.7718.72 million shs11.99 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+10.85%+4.02%+44.23%+23.64%-45.34%NVONovo Nordisk A/S+0.53%+4.96%+22.99%-3.54%-31.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.18Hold$31.8611.93% UpsideNVONovo Nordisk A/S 2.13Hold$65.5642.47% UpsideCurrent Analyst Ratings BreakdownLatest HIMS and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026HIMSHims & Hers Health Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$25.004/24/2026HIMSHims & Hers Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$35.004/24/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$30.00 ➝ $32.004/22/2026NVONovo Nordisk A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/16/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$21.00 ➝ $25.004/7/2026NVONovo Nordisk A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/27/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/27/2026HIMSHims & Hers Health TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$25.00 ➝ $23.003/26/2026NVONovo Nordisk A/S Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/18/2026NVONovo Nordisk A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/18/2026NVONovo Nordisk A/S Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$175.00(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.35B2.76$0.84 per share33.78$2.38 per share11.96NVONovo Nordisk A/S$46.80B4.39$4.68 per share9.83$7.12 per share6.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M$0.5155.8142.483.855.47%22.48%7.02%5/11/2026 (Confirmed)NVONovo Nordisk A/S$15.51B$4.2610.8013.5410.8037.23%63.31%22.19%N/ALatest HIMS and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HIMSHims & Hers Health$0.04N/AN/AN/A$616.88 millionN/A5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion3/31/2026Q1 2026NVONovo Nordisk A/SN/A$1.0270N/A$1.69N/A$10.85 billion2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.753.80%+21.74%41.08%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health1.801.901.70NVONovo Nordisk A/S0.590.790.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health13.71%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442227.94 million196.69 millionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableHIMS and NVO HeadlinesRecent News About These CompaniesLexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk MilestonesMay 10 at 5:47 AM | finance.yahoo.comIs This News From Novo Nordisk a Warning for Eli Lilly Shareholders?May 9 at 7:32 AM | fool.comOral Ozempic and Wegovy pills now available for same-day delivery on AmazonMay 9 at 3:51 AM | nypost.comNAmazon Pharmacy Access To Ozempic Pills Tests Novo Nordisk Pricing PowerMay 9 at 1:43 AM | finance.yahoo.comSector Update: Healthcare Stocks Lower Late AfternoonMay 8 at 8:42 PM | finance.yahoo.comHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)...May 8 at 11:15 AM | marketbeat.comWegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 marketMay 8 at 10:05 AM | proactiveinvestors.co.ukNovo’s CEO champions “record-breaking start” for Wegovy pill in US marketMay 8 at 9:25 AM | pharmaceutical-technology.comPEli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked OffMay 8 at 9:25 AM | finance.yahoo.comNovo Nordisk India Sales Jump 40% As Generic Pressure BuildsMay 8 at 9:25 AM | finance.yahoo.comWhat is Erste Group Bank's Estimate for NVO FY2026 Earnings?May 8 at 8:31 AM | marketbeat.comNovo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug SalesMay 8 at 5:10 AM | financialpost.comFAnalysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)May 7 at 12:54 AM | theglobeandmail.comIs Novo Nordisk (NYSE:NVO) Pricing Look Interesting After Recent Share Price Rebound?May 7 at 12:54 AM | finance.yahoo.comProthena Reports First Quarter 2026 Financial Results and Business HighlightsMay 7 at 7:54 PM | finance.yahoo.comA Look At Novo Nordisk (CPSE:NOVO B) Valuation After Oral Wegovy Success Lifts 2026 OutlookMay 7 at 7:54 PM | finance.yahoo.comAmazon adds Ozempic pill to pharmacy kiosks with same-day deliveryMay 7 at 2:53 PM | qz.comQAmazon Expands GLP 1 Push With Ozempic PillMay 7 at 2:53 PM | finance.yahoo.comAmazon Adds Same-Day Ozempic Pill DeliveryMay 7 at 2:53 PM | finance.yahoo.comForget Eli Lilly: These 2 Stocks Have More UpsideMay 7 at 2:53 PM | fool.comNovo Nordisk Surges 9.2% As Wegovy Pill Fuels MomentumMay 7 at 2:53 PM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026HIMS and NVO Company DescriptionsHims & Hers Health NYSE:HIMS$28.46 +2.81 (+10.96%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$29.07 +0.61 (+2.14%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$46.02 +0.22 (+0.48%) Closing price 05/8/2026 03:59 PM EasternExtended Trading$45.87 -0.15 (-0.33%) As of 05/8/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
